Just two weeks after filing for a $100 million initial public offering, ArcherDx agreed to be acquired by Invitae for up-to-approximately $1.4 billion, in a deal the companies said would create a ...

Invitae is facing two main challenges - assembling a coherent business model from dozens of acquisitions and avoiding a cash crunch looming in 2024/2025. The company has taken decisive action to ...

"We congratulate Invitae on its first CE-IVD cancer testing kits, a significant milestone." FusionPlex ® Dx identifies structural variants including fusions in RNA derived from formalin-fixed, ...

Invitae is among the companies pioneering genomics. The company is building a platform that can use DNA to drive smarter healthcare decision-making throughout various life stages. However, the company ...